CoChat

Unique Phenotypic Characteristics and Clinical Course in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis: A Multicenter US Experience

Open access

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

Introduction: Ulcerative colitis (UC) associated with primary sclerosing cholangitis (PSC) is a rare phenotype. We aimed to assess patients with UC-PSC or UC alone and describe differences in clinical and phenotypic characteristics, antitumor necrosis factor (TNF) therapy, and long-term clinical outcomes. Methods: This retrospective multicenter cohort study included patients who received a diagnosis of UC from 1962 through 2015. We evaluated clinical factors associated with UC-PSC vs UC alone and assessed associations by using multivariable logistic regression models. Results: Among 522 patients with UC, 56 (10.7%) had PSC. Compared with UC alone, patients with UC-PSC were younger (younger than 20 years) at diagnosis (odds ratios [OR], 2.35; adjusted P = 0.02) and had milder UC severity (adjusted P = 0.05), despite having pancolonic involvement (OR, 7.01; adjusted P < 0.001). In the biologics era (calendar year 2005 to 2015), patients with UC-PSC less commonly received anti-TNF therapy compared with patients with UC (OR, 0.38; adjusted P = 0.009), but their response rates were similar. Fewer patients with UC-PSC received corticosteroids (OR, 0.24; adjusted P = 0.005) or rectal 5-aminosalicyte acid (OR, 0.26; adjusted P < 0.001). Other differences were identified that were not statistically significant in a multivariable model: patients with UC-PSC more commonly were male, had lower rates of smoking, and had higher rates of colorectal cancer and colectomy. Discussion: This study identified a unique phenotype of UC with concurrent PSC, which had different clinical behavior compared with UC only. These phenotypic characteristics can help identify high-risk patients with UC before PSC is diagnosed and guide different management and monitoring strategies.

Overview

Integrity signals

Registry

Crossref · 10.1093/ibd/izz209

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Research works printed but not linked: 1

  1. Dignass, 2015, Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management (Spanish version), Rev Gastroenterol Mex., 80, 32

Cited by

Metadata

Authors
Wang, M.-H., Mousa, O. Y., Friton, J. J., Raffals, L. E., Leighton, J. A., Pasha, S. F., Picco, M. F., Cushing, K. C., Monroe, K., Nix, B. D., Newberry, R. D., & Faubion, W. A.
Affiliations
  • Mayo Clinic (US)
  • Washington University in St. Louis (US)
Corresponding author
Wang, Ming-Hsi
Venue
Inflammatory Bowel Diseases
Published
2019-10-18
Volume
26
Issue
5
Pages
774-779
ISSN
  • 1078-0998 (ISSN-L)
  • 1536-4844
OpenAlex
W2980461461
Cited by
27
References
38
Citations by year
2026: 5 · 2025: 5 · 2024: 3 · 2023: 4 · 2022: 5 · 2021: 2 · 2020: 2 · 2019: 1
FWCI
1.50
Type
journal article
Language
en
Open access
Locations
  • Inflammatory Bowel Diseases (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Helmsley Charitable Trust
  • National Institutes of Health (T32DK007130)
  • Washington University Institute of Clinical and Translational Sciences (UL1TR000448)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
ulcerative colitis, primary sclerosing cholangitis
MeSH terms
Tumor Necrosis Factor Inhibitors, Adolescent, Adult, Colitis, Ulcerative, Female, Humans, Male, Middle Aged, Phenotype, Retrospective Studies, Severity of Illness Index, Sex Factors, United States, Cholangitis, Sclerosing, Logistic Models, Odds Ratio, Treatment Outcome, Disease Management, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.